Letonya - Letonca - Zāļu valsts aģentūra

sun pharmaceutical industries europe b.v., netherlands - klaritromicīns - apvalkotā tablete - 500 mg

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiski līdzekļi - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Letonya - Letonca - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - metformīna hidrohlorīds - apvalkotā tablete - 850 mg

Letonya - Letonca - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - metformīna hidrohlorīds - apvalkotā tablete - 500 mg

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).

Avrupa Birliği - Letonca - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - cukura diabēts - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Letonya - Letonca - Zāļu valsts aģentūra

laboratori guidotti s.p.a., italy - metformīna hidrohlorīds - apvalkotā tablete - 1000 mg

Letonya - Letonca - Zāļu valsts aģentūra

merck sante s.a.s., france - metformīna hidrohlorīds - apvalkotā tablete - 500 mg

Letonya - Letonca - Zāļu valsts aģentūra

merck sante s.a.s., france - metformīna hidrohlorīds - ilgstošās darbības tablete - 1000 mg